Fredun Pharma Peer Comparison

BSE: 539730

₹1,476.60

₹-16.10 (-1.08%)

As on 28-Aug-2026IST

Market cap

₹2,443 Cr

Revenue (TTM)

₹748 Cr

P/E Ratio

55.7

P/B Ratio

8.3

Div. Yield

0 %

Edit

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	2,443	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	748	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	43.82	414.00	288.22	-371.81	387.35
Net Margin (%)	5.86	11.23	14.79	-3.93	26.01
RoE (%)	20.13	8.38	29.77	-3.85	25.18
Price to Earnings	55.74	78.49	103.71	--	69.57
Price-To-Book	8.33	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	635.47	3,373.00	1,753.96	8,869.08	1,006.88
Total Income	639.12	3,510.00	1,762.66	9,111.51	1,023.80
Total Expenditure	544.56	2,747.00	1,354.69	7,976.59	774.80
EBITDA	90.91	626.00	399.26	892.49	232.07
Depreciation	8.25	227.00	45.26	831.24	26.62
EBIT	82.66	399.00	354.00	61.25	205.45
Interest	39.32	213.00	42.17	340.80	6.22
Other Income	3.66	137.00	8.70	242.43	16.93
Exceptional Items	--	-85.00	--	-196.14	--
Profit before Tax	47.00	238.00	320.53	-176.06	216.16
Provision for Tax	14.38	39.00	73.80	149.88	55.75
Profit after Tax	32.62	199.00	246.74	-325.94	160.42

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	278.11	4,940.00	1,288.82	8,162.62	1,309.63
Minority Interest	0.00	341.00	0.00	--	10.45
Non-Current Liabilities	67.11	1,235.00	189.02	4,529.41	26.93
Current Liabilities	296.86	1,622.00	835.87	4,874.74	202.25
Total Liabilities	642.08	8,578.00	2,326.71	17,723.32	1,549.26

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	143.91	5,441.00	631.90	10,258.66	757.63
Current Assets	498.17	2,606.00	1,681.81	7,308.11	791.64
Total Assets	642.08	8,578.00	2,326.71	17,723.32	1,549.26
Total Debt*	222.40	2,125.00	259.37	5,495.48	8.18
Net Current Assets	201.31	984.00	845.94	2,433.37	589.39
Contingent Liabilities	--	768.26	19.09	95.72	15.38

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	11.90	390.00	205.05	1,652.60	118.34
Cash Flow from Investing Activities	-73.59	-241.00	-409.72	-826.03	-223.94
Cash from Financing Activities	121.45	-54.00	283.07	-38.98	261.12
Net Cash Inflow / Outflow	59.76	95.00	78.39	787.59	155.52

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	21.34	6.79	29.22	1.24	20.14
ROE (%)	16.09	4.29	27.84	-4.04	16.19
ROA (%)	5.78	2.53	13.11	-1.98	12.13
EBIT Margin (%)	14.88	22.62	23.26	12.80	24.73
Net Margin (%)	5.10	5.67	14.00	-3.58	15.67
Cash Profit Margin (%)	6.43	10.98	7.71	4.80	18.58

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	40.03	11.99	36.57	-3.08	40.34
EBIT Growth (%)	72.22	67.69	52.29	-28.15	83.12
Net Profit Growth (%)	65.26	449.12	83.64	-457.66	229.35
EPS Growth (%)	42.59	553.20	71.44	-456.91	67.16
Book Value Growth (%)	86.87	13.47	144.31	0.33	94.96

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	28.05	89.54	51.69	0.00	62.97
Price / Book Value	3.46	3.87	10.14	2.24	15.26
Dividend Yield (%)	0.04	0.00	0.19	0.00	0.06
EV/EBITDA	11.34	27.45	31.05	19.72	79.31
Market Cap (₹ Cr)	914.95	19,071.62	12,753.19	18,108.89	19,988.69

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.84	0.43	0.21	0.68	0.01
Short term debt to equity ratio	0.53	0.09	0.05	0.09	0.01
Current Ratio	1.68	1.61	2.01	1.50	3.91
Quick Ratio	0.77	1.06	1.14	0.87	3.02
Interest Coverage	2.20	2.12	8.60	0.48	35.76

	Fredun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	14.59	17.43	29.00	24.33	28.85
Asset Turnover	1.13	0.49	2.01	0.64	0.76
Receivable days	77.49	58.75	40.13	78.20	90.06
Inventory Days	146.38	75.82	60.29	93.30	61.02
Payable days	93.37	186.21	232.47	226.14	96.06
Cash Conversion Cycle	130.49	-51.64	-132.04	-54.64	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.